Medexus Pharmaceuticals (TSX:MDP) Shiller PE Ratio: (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
52 GF Score
Price C$5.06
GF Value C$2.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medexus Pharmaceuticals  (TSX:MDP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Medexus Pharmaceuticals Shiller PE Ratio Related Terms


Medexus Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Shiller PE Ratio Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medexus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSX:MDP vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Shiller PE Ratio falls into.


TSX:MDP
52GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medexus Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Medexus Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.028/133.5265*133.5265
=0.028

Current CPI (Jun. 2026) = 133.5265.

Medexus Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.179 101.765 -0.235
201612 -0.149 101.449 -0.196
201703 -0.227 102.634 -0.295
201706 -0.215 103.029 -0.279
201709 -0.059 103.345 -0.076
201712 -0.173 103.345 -0.224
201803 -0.168 105.004 -0.214
201806 -0.120 105.557 -0.152
201809 -0.625 105.636 -0.790
201812 -0.099 105.399 -0.125
201903 0.027 106.979 0.034
201906 -0.152 107.690 -0.188
201909 0.040 107.611 0.050
201912 -0.192 107.769 -0.238
202003 -0.161 107.927 -0.199
202006 -0.325 108.401 -0.400
202009 -0.146 108.164 -0.180
202012 -1.127 108.559 -1.386
202103 -0.792 110.298 -0.959
202106 -0.415 111.720 -0.496
202109 0.659 112.905 0.779
202112 -0.090 113.774 -0.106
202203 -0.342 117.646 -0.388
202206 -0.090 120.806 -0.099
202209 -0.187 120.648 -0.207
202212 -0.095 120.964 -0.105
202303 0.465 122.702 0.506
202306 0.040 124.203 0.043
202309 -0.068 125.230 -0.073
202312 -0.027 125.072 -0.029
202403 0.054 126.258 0.057
202406 0.110 127.522 0.115
202409 0.000 127.285 0.000
202412 0.043 127.364 0.045
202503 -0.043 129.181 -0.044
202506 0.027 129.892 0.028
202509 -0.014 130.287 -0.014
202512 0.000 130.366 0.000
202603 -0.110 132.262 -0.111
202606 0.028 133.527 0.028

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.06 is trading 144.4% above its estimated GF Value™ of C$2.07. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Shiller PE Ratio:
  • GF Value™: C$2.07 vs. price of C$5.06 (144.4% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
52GF Score

Get the complete analysis for TSX:MDP

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.06
Price
C$2.07
GF Value